VivoSeq
Other

Adverse Drug Reactions

0

Pipeline Programs↗

1

Active Trials↗

1

Companies Involved↗

Adverse Drug Reactions is an early-stage landscape with 0 programs across 1 company. The most active players are Eisai.

Intelligence

Pipeline Metrics

Competitive Density

6/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Eisai logo

Eisai

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

10

clinical trials

Completed7 · 70%
Unknown status2 · 20%
Active, not recruiting1 · 10%

Clinical Trials

Trial Activity

10 trials

Effect of Epstein-Barr Virus on Macrophage M2/M1 Migration and EphA2 Expression in Adverse Drug Reactions
Active, not recruiting·FFirst Affiliated Hospital of Kunming Medical University·N/A·NCT06456086·27 enrolled
Adverse Drug Reactions With Fatal Outcome
Completed·GGermans Trias i Pujol Hospital·N/A·NCT02838212·1,135 enrolled
Evaluation of TNF-α Blockade Effect in Patients With Severe Cutaneous Adverse Drug Reactions
Completed·—·N/A·NCT01276314·135 enrolled
Adverse Drug Reactions to Cancer Therapies in Patients with Depression: Insights from VigiBase
Completed·UUniversity Hospital, Caen·N/A·NCT06801158·8,804,863 enrolled
Hospital Intensive Monitoring of Adverse Drug Reactions of Qingkailing Injection In The Next Two Years
Completed·CChina Academy of Chinese Medical Sciences·N/A·NCT01764204·30,840 enrolled
A Study of Equfina® on the Incidences of Adverse Drug Reactions in Participants With Parkinson's Disease (Including Participants With Hepatic Impairment)
Completed·Eisai logoEisai·N/A·NCT04724109·1,088 enrolled
Prevalence and Causes of Preventable and Serious Adverse Drug Reactions Related to the Use of Oral Anticoagulants
Completed·CCliniques universitaires Saint-Luc- Université Catholique de Louvain·Phase 4·NCT02720328·102 enrolled
Registry Type Study to Monitor for Adverse Drug Reactions to Fedoruk Manufactured [F-18]-Fludeoxyglucose
Completed·UUniversity of Saskatchewan·Phase 4·NCT02811185·1,012 enrolled
Adverse Drug Reactions of Different Brands of Ceftazidime Injection
Unknown status·NNational Taiwan University Hospital·Phase 4·NCT00173901·536 enrolled
Study on the Adverse Drug Reactions (ADRs) of Apatinib and Their Biomarker Correlations
Unknown status·SSun Yat-sen University·Phase 4·NCT03475589·217 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)